Full-Time

CSV Systems Engineer 2/3

Curia

Curia

1,001-5,000 employees

End-to-end drug development and manufacturing

Compensation Overview

$73k - $112k/yr

Albany, NY, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Operating Systems
Risk Management
Requirements
  • Bachelor’s Degree in Information Technology or related field
  • Minimum 3 years’ experience in quality and computer systems validation and/or information technology
Responsibilities
  • Manage multiple site and global CSV projects at any time
  • Maintain close communication with stakeholders and team members to keep apprised of computerized system needs, impacts on computer validation, project validation status, and other relevant issues
  • Create all CSV deliverables for all CSV projects
  • Provide expertise in SOP generation and CSV process
  • Own general configuration modification to any CSV system based on CSV compliance standards
  • Provide expertise on creation of CSV execution templates
  • Perform CSV risk assessments
  • Own CSV change records, CAPAs and Quality events for the CSV projects
  • Act as CSV reviewer on any CSV defects/deviations within any project
  • Support Site and global CSV actions from any audits
  • Participate in all site audits/inspections as CSV subject matter expert
  • Provide guidance and resolution on quality issues that affect the integrity of the data or the system
  • Gather inventory and maintain all scientific applications and computer systems within Curia sites (GMP and non-GMP)
  • Inform Service Engineer I of any changes in software and hardware status
  • Support Lab Ops team to ensure all computer systems has up to date Antivirus software
  • Support Lab Ops team to ensure all computer systems have a backup software installation
  • Support Lab Ops team in updating computer systems that are running outdated Operating systems
  • Perform monthly patching auditing risk assessments with Lead CSV Compliance Analyst
  • Execute periodic reviews and data collection
  • Participate in all site audits /inspections as a CSV subject matter expert
  • Provide routine project status reports
  • Provide routine software and hardware inventory updates
  • Provide routine progress updates on SOPs and Templates
  • Provide CAPA, QE and CR updates to compliance team
  • Provide routine audit observations and remediations
Desired Qualifications
  • Experience in the pharmaceutical industry

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$1.1B

Headquarters

Albany, New York

Founded

1991

Simplify Jobs

Simplify's Take

What believers are saying

  • Biologics segment expansion under Steve Lavezoli accelerates high-margin pharmaceutical outsourcing revenue growth.
  • Carterra partnership positions Curia to capture Pacific Northwest biotech demand in antibody discovery services.
  • Gerald Auer's CFO appointment signals M&A activity and potential strategic initiatives enhancing shareholder value.

What critics are saying

  • Pace Life Sciences acquisition of New Jersey lab erodes Curia's analytical testing capacity and revenue.
  • Larger CDMOs like Lonza and Catalent undercut Curia on biologics capacity, stealing biotech contracts.
  • FDA scrutiny on srRNA manufacturing defects from Replicate Bioscience Phase 1 triggers potential client exodus.

What makes Curia unique

  • Pioneer in self-replicating RNA manufacturing, demonstrated through Replicate Bioscience Phase 1 clinical trial support.
  • Integrated enzymatic doggybone DNA technology via Touchlight collaboration expands mRNA manufacturing competitive advantages.
  • End-to-end CDMO services from discovery through cGMP manufacturing differentiate Curia from specialized competitors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
The Carlyle Group
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb.com
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

PPI News Agency
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.